Matching articles for "tradipitant"
Issue 1757 · June 22, 2026
Tradipitant (Nereus) for Motion Sickness

The FDA has approved the oral substance P/neurokinin-1 (NK-1) receptor antagonist tradipitant ( Nereus – Vanda) for prevention of vomiting induced by motion in adults. Tradipitant is the first drug to be…

Med Lett Drugs Ther. 2026 Jun 22; 68(1757):97-8 doi:10.58347/tml.2026.1757a
The FDA has approved the oral substance P/neurokinin-1 (NK-1) receptor antagonist tradipitant ( Nereus – Vanda) for prevention of vomiting induced by motion in adults. Tradipitant is the first drug to be approved for motion sickness in more than 40 years. Other oral substance P/NK-1 receptor antagonists (i.e., aprepitant, rolapitant, and netupitant) have been available for years for prevention of chemotherapy-induced nausea and vomiting.
Issue 1757 · June 22, 2026 Free
Comparison Chart: Drugs for Motion Sickness (online only)

View the Comparison Chart: Drugs for Motion Sickness

Med Lett Drugs Ther. 2026 Jun 22; 68(1757):e98 doi:10.58347/tml.2026.1757g
View the Comparison Chart: Drugs for Motion Sickness